Lung cancers can use two different mechanisms to evade KRAS-inhibiting drug, MIT researchers find

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

About 25% of lung adenocarcinomas have mutations of the gene KRAS, which drives uncontrolled cell growth. In recent years, FDA has approved two KRAS inhibitors to treat patients with  specific KRAS mutations. While these drugs can work well initially, tumors almost always develop resistance to them.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Tagrisso (osimertinib) demonstrated a sustained, clinically meaningful overall survival benefit at eight years compared to placebo in the adjuvant treatment of patients with early-stage (1B, 2, and 3A) epidermal growth factor receptor-mutated non-small cell lung cancer after complete tumor resection with curative intent, according to the updated exploratory results from the ADAURA phase III trial. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login